Xynomic Research Institute (XRI), a subsidiary of Xynomic Pharmaceuticals Holdings, has designed a series of potent RET kinase inhibitors by computer-assisted drug design, it was reported yesterday.
The company's cRET kinase inhibitors are a range of acetylene derivatives with novel and stable structures. Preliminary activity tests indicated that they showcased outstanding selectivity and inhibitory activity against TT tumour cells, and some compounds were identified as having submicromolar IC50 values in the mid- to low-nanomolar range. Further structure-activity relationship studies are presently underway to screen and receive lead compounds.
Y Mark Xu, chairman and CEO of Xynomic, said, 'XRI focuses on research and development of innovative oncology drug candidates. We have recently upgraded our infrastructure and equipment and hired additional scientists. We believe that we are now well positioned to fully leverage XRI's capacity to efficiently design and synthesise cutting edge molecules.'
XRI has already filed global patents for internally discovered pre-clinical drug candidates XP-103 and XP-104.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886